Polycystic ovary syndrome (PCOS) has been officially renamed polyendocrine metabolic ovarian syndrome (PMOS) after a comprehensive 14-year effort. This change, announced at the European Congress of Endocrinology in Prague, aims to clarify the condition's nature, which affects approximately one in eight women worldwide. Experts argue that the previous name misrepresented the disorder, which is primarily hormonal and metabolic, and often does not involve actual ovarian cysts. Professor Helena Teede, an endocrinologist from Australia, emphasized that the term PCOS led to confusion and misdiagnosis, as many patients experience symptoms such as irregular periods, infertility, and weight gain without visible cysts. The World Health Organization estimates that nearly 70% of individuals with the condition remain undiagnosed. The renaming initiative involved collaboration among thousands of healthcare professionals and patient organizations globally, and awareness campaigns will continue for the next three years to ensure the new terminology is adopted widely.